Parkin encodes an E3 ubiquitin ligase, and mutations affecting its catalytic potential are implicated in autosomal recessive Parkinson's disease (PD). The M458L mutation of parkin and its enzymatic effects require characterization. Therefore, we examined the enzymatic activity of Parkin with M458L mutation. We show that the M458L mutant retains its autoubiquitination potential in vitro but not in cells. Fas-associated factor 1 and p38 (substrates of Parkin) are able to bind to the M458L mutant in cells; however, these Parkin substrates are not ubiquitinated and degraded in M458L mutant-transfected cells. Moreover, M458L mutant fails to protect the mitochondria against hydrogen peroxide , leading to cell death. Considering the role of mitochondrial dysfunction in PD pathogenesis, our results imply a causative role for the M458L mutation in neurodegeneration.
of Parkin dysregulation in PD [13, 23, 32, 41, 42] . Indeed, increased expression of Parkin substrates such as Fasassociated factor 1 (FAF1) and p38 in the brains of PD patients causes dopaminergic neuron death in Parkin-related PD [42, 43] .
We previously reported the presence of the M458L mutation, which is localized in the C terminus of parkin, in Korean PD patients [44] . Two cases of PD patients with the M458L mutation have been reported in the global clinical literature, and one additional case was identified among 582 Korean PD patients, indicating the rare occurrence of the M458L mutation [4, [45] [46] [47] . However, the biochemical characteristics of the M458L mutation have yet to be clarified. Therefore, this study sought to elucidate the effect of the M458L mutation on the Parkin function.
Here, we report that an M458L mutant retains its autoubiquitination ability in vitro, but the mutation abolishes the enzymatic activity of Parkin in a cellular context. Therefore, the M458L mutation results in the accumulation of Parkin substrates, which might be detrimental to neurons.
Materials and methods

Reagents
Human embryonic kidney 293 (HEK293) cells were transfected using BioT reagent (Bioland Scientific LLC, Paramount, CA, USA). The following antibodies were purchased: mouse anti-FLAG (Sigma-Aldrich, Saint Louis, MI, USA), mouse anti-b-actin (Sigma-Aldrich), mouse anti-ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-Parkin (Santa Cruz Biotechnology), mouse anti-S1 (MyBioSource Inc., San Diego, CA, USA), anti-Myc (AbFrontier, Seoul, Korea), rabbit anti-GAPDH (AbFrontier), horseradish peroxidase (HRP)-conjugated anti-mouse (Thermo Fisher Scientific Inc., Rockford, IL, USA), and HRP-conjugated anti-rabbit (Thermo Fisher Scientific Inc.), as well as anti-FLAG beads (Sigma-Aldrich). The following chemical reagents were purchased: MG132 (Sigma-Aldrich), cycloheximide (CHX; Sigma-Aldrich), and propidium iodide (PI; SigmaAldrich). Parkin mutants were generated using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
Cell culture
The HEK293 cells were cultured in DMEM (WelGENE, Daegu, Korea) supplemented with FBS (10%; Atlas Biologicals, Fort Collins, CO, USA), and penicillin/streptomycin (1%) in a humidified atmosphere (37°C, 5% CO 2 ).
Plasmid construction and site-directed mutagenesis
Parkin mutants were generated using a QuikChange sitedirected mutagenesis kit (Stratagene) on the pMS1-2-S1-Parkin template according to the manufacturer's protocol. The sequences of the mutants were confirmed by a sequence analysis service (Cosmogenetech, Ltd., Seoul, Korea).
Cell transfection
The HEK293 cells (3 9 10 5 cells) were plated in 60-mm dishes and transfected with the final constructed plasmids using BioT reagent. Twelve hours after the addition of a DNA-BioT mixture, the medium was replaced. Forty-eight hours after transfection, the cells were harvested.
In vitro ubiquitination assay
GST-tagged wild-type (WT) Parkin and M458L mutant proteins were purified from the bacteria using glutathionesepharose beads. The Glutathione S-transferase (GST)-fusion proteins were mixed with ubiquitination buffer (50 mM Tris-HCl; pH 7.4, 2 mM ATP, 5 mM MgCl 2 , 2 mM DTT, 30 mM creatine phosphate and 0.05 mgÁmL À1 creatine phosphokinase), rabbit E1 (200 ng; Calbiochem, Darmstadt, Germany), UbcH7 (100 ng; Calbiochem), and ubiquitin (Ub; 5 mg, Sigma-Aldrich). The reactions were incubated at 30°C for 2 h and stopped with SDS-loading buffer. The proteins were separated by SDS/PAGE and analyzed by western blotting.
Immunoprecipitation
The HEK293 cells were lysed in lysis buffer [Tris-HCl (20 mM; pH 7.5), NaCl (150 mM), EDTA (2 mM), NP-40 (1%), PMSF (0.4 mM), glycerol 2-phosphate (25 mM), Na 3 VO 4 (1 mM), DTT (1 mM), and NaF (1 mM)], vortexed and then centrifuged at 12 000 g for 10 min at 4°C. The resulting whole-cell lysates (WCLs) were incubated with anti-Parkin antibody and protein A/G agarose beads (Santa Cruz Biotechnology) for 12 h at 4°C. Immunocomplexes were washed three times with mammalian lysis buffer, and sample buffer was added. The supernatants were subjected to SDS/PAGE and immunoblotted with the indicated antibodies.
SDS/PAGE and western blot analysis
The HEK293 cells were lysed with lysis buffer, and protein concentrations were then determined using the Bradford method. The WCLs were separated by SDS/PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5% skim milk and incubated with the indicated antibodies at 4°C for 12 h. After washing three times for 10 min, the membranes were incubated with HRPconjugated secondary anti-mouse or HRP-conjugated secondary anti-rabbit antibodies for 1 h. Protein bands were visualized using ECL detection kits (YounginFrontier, Anyang, Korea).
Cycloheximide chase assay
The HEK293 cells were transfected with WT Parkin or the M458L mutant. At 48 h after transfection, cells were treated with 20 lgÁmL À1 CHX and chased for the indicated time periods. Then, the cells were harvested. The resulting WCLs were separated by SDS/PAGE and analyzed by western blotting with the indicated antibodies.
Measurement of mitochondrial membrane potential
The HEK293 cells were transfected with WT Parkin or the M458L mutant for 44 h. Subsequently, cells were treated with 0.5 mM hydrogen peroxide (H 2 O 2 ) for 4 h. Mitochondrial membrane potential was measured using a Muse MitoPotential kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Briefly, cells were incubated with Muse MitoPotential dye for 20 min in a 37°C CO 2 incubator, and changes in mitochondrial membrane potentials were determined with a Muse analyzer (Millipore).
Flow cytometry
The HEK293 cells were transfected with WT Parkin or the M458L mutant for 36 h. Subsequently, the cells were treated with 0.5 mM H 2 O 2 for 12 h. The cells were harvested and washed three times with PBS. Following centrifugation, the cells were stained with 5 lgÁmL À1 PI for 10 min at 37°C in the dark. Cell death was analyzed using a Guava easyCyte flow cytometer (Millipore). All experiments were repeated three times.
Statistical analysis
At least ≥ 3 independent experiments were performed in vitro and in cells. All data are expressed as the mean AE standard deviation (SD). The statistical significance of differences between the experimental and control groups was evaluated by performing two-tailed t-tests. Pvalues < 0.05 were considered significant.
Results
The M458L mutant retains its autoubiquitination potential in vitro but not in a cellular context
Parkin autoubiquitination has been established as a reliable method for evaluating the enzymatic function of Parkin [23, 48, 49] . Therefore, we examined whether a Parkin M458L mutation affected autoubiquitination activity in vitro. To address this issue, GST-Parkin WT and GST-Parkin M458L mutant proteins were purified from Escherichiea coli strain BL21. The GSTfusion proteins were incubated with ATP, Ub, E1, and UbcH7 and subjected to immunoblotting with antiParkin and anti-Ub antibodies. High molecular mass ladders derived from autoubiquitination were observed for both GST-Parkin WT and GST-Parkin M458L (Fig. 1A) , indicating that the M458L mutation did not impair Parkin catalytic ability in vitro. Next, we examined whether the Parkin M458L mutation affected its autoubiquitination activity in the cellular context. We transfected S1-WT Parkin and the S1-M458L mutant together with HA-Ub into HEK293 cells. Subsequently, immunocomplexes precipitated with an anti-S1 antibody were analyzed by performing western blotting using an anti-Ub antibody. WT Parkin was autoubiquitinated in HEK293 cells, but the M458L mutant was not (Fig. 1B) . This discrepancy in the enzymatic abilities of the WT protein and Parkin mutant under in vitro conditions and in cells was also previously reported for the T240R mutant [18, 50] .
The Parkin M458L mutation impairs the solubility and the ubiquitination potential of Parkin Based on our finding that the M458L mutant failed to ubiquitinate itself in a cellular context, we investigated whether the M458L mutation alters the solubility of Parkin. To address this issue, M458L mutant was analyzed for its ability to be extracted by two detergents, Triton X-100 and SDS in HEK293 cells. Equal amount of WT Parkin was observed in both soluble and insoluble fractions upon Triton X-100/SDS treatment ( Fig. 2A) . In contrast, more amount of M458L mutant was observed in insoluble fraction, implying that M458L mutation altered the solubility of Parkin.
We next examined whether the M458L mutation affected the ability of PArkin to ubiquitinate substrates in cells. HEK293 cells were transfected with the indicated combinations of 3xFlag-FAF1, 3xFlag-p38, Parkin WT, and Parkin M458L. Subsequently, cell lysates were immunoprecipitated with an anti-Flag antibody followed by western blotting with anti-Ub and anti-Flag antibodies. Ubiquitination of the substrates was significantly attenuated by M458L mutation, whereas Parkin WT was competent to ubiquitinate substrates (Fig. 2B,C) . Based on these data, the M458L mutation disrupted the capacity of Parkin to ubiquitinate its substrates.
Next, we examined whether the M458L mutation affected the ability of Parkin to degrade its substrates in a cellular context. To determine whether substrates were degraded in the presence of the Parkin M458L mutant, the decay rates of the substrate proteins were examined in HEK293 cells expressing 3xFlag-FAF1 or Myc-p38 that were transfected with S1-Parkin WT and the M458L mutant. HEK293 cells transfected with WT Parkin and the M458L mutant were treated with CHX for the indicated time periods. In the presence of WT Parkin, the expression of FAF1 and p38 gradually decreased (Fig. 2D,E) , which indicated that FAF1 and p38 were degraded by WT Parkin. In contrast, FAF1 and p38 degradation was significantly attenuated in the presence of the Parkin M458L mutant (Figs 2D,E and S1), which indicated that the M458L mutant was defective in its ability to degrade the substrates.
The Parkin M458L mutant maintains the ability to bind its substrates To investigate the mechanisms by which the Parkin M458L mutant exerted its loss-of-function phenotype, we examined whether the Parkin M458L mutant binds to its substrates. We transfected S1-Parkin WT, S1-Parkin M458L, and S1-Parkin T240R into HEK293 cells expressing 3xFlag-FAF1 or 3xFlag-p38. The T240R mutant served as a positive control. Probing the immunoprecipitated samples with an anti-Flag antibody on a western blot revealed that the M458L mutant and the T240R mutant were able to bind both FAF1 and p38 (Fig. 3A,B) . Thus, the M458L mutation does not affect the substrate-binding capacity of Parkin in a cellular context.
The Parkin M458L mutant fails to protect mitochondria resulting cell death upon H 2 O 2
We next examined whether the M458L mutation damaged the mitochondria in H 2 O 2 -injured cells because oxidative stress is implicated in the pathogenesis of PD [51] [52] [53] [54] . H 2 O 2 treatment, which is commonly used to induce oxidative stress [55] , caused mitochondrial depolarization in HEK293 cells when examined with a Muse analyzer (Fig. 4A) . Transfection of the Parkin WT decreased the extent of mitochondrial depolarization in HEK293 cells upon H 2 O 2 exposure, whereas that of the M458L mutant did not. Next, we investigated whether the M458L mutation affected cell death in response to H 2 O 2 . The extent of cell death in M458L-transfected HEK293 cells was greater than that in WT Parkin-transfected HEK293 cells (Fig. 4B) , indicating that Parkin protects cells against H 2 O 2 , and M458L mutation impairs its protective potential. The results were consistent with our previous study that depletion of Parkin increases MPP + -induced cell death in SH-SY5Y cells [16] .
Discussion
This study investigated whether the clinical mutation M458L affected the E3 ligase function of Parkin. The M458L mutant maintained its autoubiquitination ability in vitro. However, the M458L mutant lost its autoubiquitination ability and the potential to ubiquitinate substrates in a cellular context, even though its ability to bind its substrates was maintained. Moreover, the M458L mutation resulted in the accumulation of Parkin substrates, aggravated mitochondrial depolarization and attenuated cell viability upon H 2 O 2 exposure. In addition to the T240R mutation, this is the second mutant to demonstrate a discrepancy between Parkin's catalytic abilities in vitro and in cells.
Parkin mutants are classified into three categories based on the characteristics of their defects. Mutants, such as R256C, G328E, G430D, C431F, and W453X, retain their ability to autoubiquitinate but are unable to ubiquitinate substrates [18] . A second class of mutants (K161N, T415N, and P437L) is unable to ubiquitinate themselves or their substrates [18] . The third category of mutants (T240R and Q311X) is unable to ubiquitinate either substrates or themselves but retains the ability to bind substrates [18] . The The values are expressed as the mean AE SD of three independent experiments; **P < 0.01, ***P < 0.001. Expression of S1-Parkin WT and the S1-Parkin M458L mutant were analyzed by immunoblotting using the indicated antibodies (right panel). (B) HEK293 cells were transfected with Parkin WT and the M458L mutant for 36 h. Subsequently, the cells were treated with 0.5 mM H 2 O 2 for 12 h, and cell death was measured using a flow cytometer (left panel). The values are expressed as the mean AE SD of three independent experiments; ***P < 0.001. Expression of S1-Parkin WT and the S1-Parkin M458L mutant was analyzed by immunoblotting using the indicated antibodies (right panel).
M458L mutant is included in the third group of Parkin mutants. Despite their broad spectrum of binding and ubiquitination properties, most Parkin mutations appear to affect the efficient degradation of substrates, which leads to the abnormal accumulation of substrates that are potentially toxic to cells.
Several Parkin mutants are present in the Triton Xinsoluble fraction [2, 18, 56, 57] , indicating that decreased solubility is a relatively common feature of Parkin mutants. This supposition correlates well with the presence of intracellular aggregates composed of Parkin mutants [57] [58] [59] . Therefore, we speculate that the M458L mutation also decreases the solubility of Parkin (Fig. 2E) and causes its sequestration due to ectopic localization and the subsequent formation of intracellular aggregates. Subsequently, the M458L mutation may result in the depletion of Parkin in its proper sites of action, resulting in the loss of a functional phenotype regardless of its catalytic potential.
It is worth investigating whether the M458L mutation affects Parkin's interaction with proteins involved in the ubiquitination process. For example, valosincontaining protein (VCP) is a molecular chaperone in the ubiquitin-proteasome system [60] that is recruited to the mitochondria in a manner that requires Parkindependent ubiquitination of mitochondrial proteins [61] . Moreover, the C-terminal ubiquitin regulatory X domain of FAF1 interacts with VCP, and this association regulates the binding of ubiquitin to FAF1 [60] . Another possibility is that Parkin requires additional factors, such as ubiquitin-chain elongation factors [62, 63] and E4 enzymes, for the ubiquitination process. Taken together, these findings suggest that the M458L mutation might interfere with the interaction between Parkin and partner proteins, such as VCP and E4 enzymes, to cause ubiquitination failure in a cellular context.
The domain structure of Parkin regulates its enzymatic activity [64, 65] . Parkin maintains an autoinhibitory conformation through intradomain interactions in the resting state. Stimuli that disrupt such intradomain interactions trigger enzymatic activation of Parkin. Recent studies showed that the C terminus of Parkin is important for the regulation of the enzymatic activity of Parkin [64, 66] . In particular, the Glu444 located in the C terminus constitutes a catalytic triad together with Cys431 and His433 and modulates the catalytic activity of Parkin [64] . Considering the regulatory involvement of amino acids in the C terminus in Parkin activation, it is tempting to speculate that M458L mutation might interfere with the release of the autoinhibitory conformation of intradomain interfaces because Met458 is located near the catalytic triad.
